Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amaranthus palmeri pollen is derived from Palmer's amaranth, a highly competitive and invasive weed species native to North America. [2, 13, 18] The pollen from this plant is recognized as a severe allergen, causing symptoms of allergic rhinitis (hay fever), such as sneezing, nasal congestion, and itchy, watery eyes in sensitized individuals. [1, 2, 5] Extracts of Amaranthus palmeri pollen are used for both diagnostic and therapeutic purposes. For diagnosis, allergenic extracts are used in skin prick tests to identify individuals allergic to the pollen. [1, 6] For therapy, these extracts are used in allergen-specific immunotherapy, commonly known as allergy shots. [6, 20] This treatment involves administering gradually increasing doses of the pollen extract to modulate the patient's immune system, inducing tolerance and reducing the severity of allergic symptoms upon natural exposure. [6, 20] The primary allergenic component identified in the pollen is a 14 kDa protein known as a profilin, which can cause cross-reactivity with other plant pollens and foods. [3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Amaranthus palmeri pollen.